Trials / Conditions / Recurrent Ependymoma

Recurrent Ependymoma

14 registered clinical trials studyying Recurrent Ependymoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine NCT06466798	Jeffrey Treiber	Phase 1
Active Not Recruiting	131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma NCT04743661	Pediatric Brain Tumor Consortium	Phase 2
Recruiting	ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS NCT04732065	Sabine Mueller, MD, PhD	Phase 1
Active Not Recruiting	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555	National Cancer Institute (NCI)	Phase 2
Completed	Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependym NCT03572530	The University of Texas Health Science Center, Houston	Phase 1
Active Not Recruiting	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652	National Cancer Institute (NCI)	Phase 2
Completed	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678	National Cancer Institute (NCI)	Phase 2
Completed	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2
Completed	Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors NCT02271711	M.D. Anderson Cancer Center	Phase 1
Completed	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors NCT00634231	Candel Therapeutics, Inc.	Phase 1